Claren Energy Corp. and Rxlive Limited have entered into a binding agreement with Cybin Inc. The agreement provides that RXLive will, subject to compliance with applicable privacy laws, provide Cybin with exclusive access to RXLive's customer and subscriber information relating to psychedelic products distributed through RXLive's digital pharmacy service to allow Cybin, subject to regulatory approval, to market and/or promote its psychedelic products to RXLive's customers and subscribers. RXLive will also work exclusively with Cybin to review and identify customer data for the purpose of identifying potential candidates for clinical trials in the UK.

In consideration for this access, Cybin has agreed that it will participate in the Subscription Receipt Financing (as defined below) for up to $500,000.